KCPG
NVO

Kavar Capital Partners Group’s Novo Nordisk NVO Stock Holding History

Kavar Capital Partners Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,509
Closed -$1.6M – 220
2025
Q4 		$1.6M Sell
31,509
-1,122
-3% -$57.4K 0.22% 83
2025
Q3 		$1.81M Buy
32,631
+200
+0.6% +$11.7K 0.24% 83
2025
Q2 		$2.24M Hold
32,431
– – 0.32% 70
2025
Q1 		$2.25M Buy
32,431
+832
+3% +$68.7K 0.38% 65
2024
Q4 		$2.72M Sell
31,599
-154
-0.5% -$16.7K 0.46% 58
2024
Q3 		$3.78M Sell
31,753
-420
-1% -$56K 0.6% 51
2024
Q2 		$4.59M Sell
32,173
-91
-0.3% -$12.1K 0.83% 37
2024
Q1 		$4.14M Sell
32,264
-32,564
-50% -$3.88M 0.76% 43
2023
Q4 		$6.71M Buy
64,828
+32,334
+100% +$3.2M 0.75% 43
2023
Q3 		$2.96M Sell
32,494
-1,292
-4% -$114K 0.64% 49
2023
Q2 		$2.73M Sell
33,786
-30,958
-48% -$2.53M 0.58% 55
2023
Q1 		$5.15M Sell
64,744
-2,904
-4% -$206K 1.11% 31
2022
Q4 		$4.58M Sell
67,648
-860
-1% -$50.4K 1.05% 33
2022
Q3 		$3.41M Buy
68,508
+2,900
+4% +$155K 0.87% 40
2022
Q2 		$3.65M Sell
65,608
-1,300
-2% -$72.1K 0.85% 42
2022
Q1 		$3.71M Sell
66,908
-380
-0.6% -$19.5K 0.8% 40
2021
Q4 		$3.77M Sell
67,288
-140
-0.2% -$7.58K 0.78% 39
2021
Q3 		$3.24M Sell
67,428
-500
-0.7% -$24.2K 0.74% 38
2021
Q2 		$2.85M Sell
67,928
-1,200
-2% -$46.5K 0.69% 43
2021
Q1 		$2.33M Sell
69,128
-1,700
-2% -$60.5K 0.63% 49
2020
Q4 		$2.47M Buy
70,828
+100
+0.1% +$3.46K 0.71% 45
2020
Q3 		$2.46M Buy
70,728
+400
+0.6% +$13.3K 0.83% 41
2020
Q2 		$2.3M Buy
70,328
+5,400
+8% +$172K 0.88% 38
2020
Q1 		$1.95M Sell
64,928
-1,750
-3% -$52.1K 0.94% 35
2019
Q4 		$1.93M Buy
66,678
+800
+1% +$22.2K 0.71% 52
2019
Q3 		$1.7M Buy
65,878
+5,854
+10% +$148K 0.66% 55
2019
Q2 		$1.53M Buy
60,024
+8,426
+16% +$208K 0.6% 58
2019
Q1 		$1.35M Buy
51,598
+200
+0.4% +$4.92K 0.6% 61
2018
Q4 		$1.18M Sell
51,398
-5,900
-10% -$131K 0.64% 60
2018
Q3 		$1.35M Buy
57,298
+1,500
+3% +$36.6K 0.67% 62
2018
Q2 		$1.29M Buy
55,798
+900
+2% +$21.4K 0.65% 57
2018
Q1 		$1.35M Sell
54,898
-500
-0.9% -$13.1K 0.71% 58
2017
Q4 		$1.49M Sell
55,398
-1,400
-2% -$35.6K 0.79% 56
2017
Q3 		$1.37M Buy
56,798
+5,600
+11% +$127K 0.75% 58
2017
Q2 		$1.1M Sell
51,198
-1,800
-3% -$36.3K 0.6% 62
2017
Q1 		$908K Buy
52,998
+6,950
+15% +$121K 0.51% 70
2016
Q4 		$826K Buy
46,048
+5,900
+15% +$107K 0.52% 67
2016
Q3 		$835K Buy
+40,148
New +$995K 0.54% 69

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Kavar Capital Partners Group's NVO Position: Q1 2026 in Review

Kavar Capital Partners Group sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 31,509 shares — an estimated $1.6M sold.

Kavar Capital Partners Group first reported a position in NVO in Q3 2016 and held it in 38 quarters. The position peaked at $6.71M in Q4 2023. 1,270 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Kavar Capital Partners Group reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Kavar Capital Partners Group sold 31,509 Novo Nordisk shares in Q1 2026, an estimated $1.6M.
  • Kavar Capital Partners Group first reported a position in Novo Nordisk in Q3 2016 and held it in 38 quarters.
  • Kavar Capital Partners Group's Novo Nordisk position peaked at $6.71M in Q4 2023.
  • 1,270 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Kavar Capital Partners Group's 13F filing for Q1 2026, filed 16 Apr 2026.